Skip to main content

Table 1 Demographic and clinical characteristics of study participants (n = 100)

From: Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia

Age group
  < 1455%
  > 6422%
Treatment history
 A loss to follow up44.4%
Specimen type
Extrapulmonary samples
 Lymph node1950.0%
 Pleural fluid513.2%
 Ascetic fluid38.0%
 Unspecified body fluid25.2%